Health Catalyst, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCAT research report →
Range $1.75 – $1.8
Price Chart
About the company
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector.
- CEO
- Simeon Kohl
- IPO
- 2019
- Employees
- 1,200
- HQ
- South Jordan, UT, US
Get TickerSpark's AI analysis on HCAT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $99.76M
- P/E
- -0.46
- Fwd P/E
- 16.38
- PEG
- 0.01
- P/S
- 0.36
- P/B
- 0.67
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
- Gross Margin
- 44.80%
- Op Margin
- -20.47%
- Net Margin
- -74.24%
- ROE
- -128.24%
- ROIC
- -34.20%
Latest fiscal year · YoY change
- Revenue
- $311.14M+1.5%
- Gross Profit
- $104.13M-26.0%
- Op Income
- $-36,104,000
- Net Income
- $-177,974,000-156.1%
- EPS
- $-2.55-121.7%
- OCF Growth
- -95.0%
- FCF Growth
- +87.1%
- 52W High
- $3.03
- 52W Low
- $0.95
- 50D MA
- $1.65
- 200D MA
- $1.66
- Beta
- 1.53
- RSI (14)
- 37
- Avg Volume
- 414.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Health Catalyst beat third-quarter expectations and reaffirmed full-year guidance, while management shifted the focus to retention, cost alignment, and simplifying the business.· November 5, 2026
- Q3 revenue was $56.3 million and adjusted EBITDA was $779,000, both above the high end of guidance.
- Full-year 2026 revenue guidance was reaffirmed at $246 million-$249 million and adjusted EBITDA at $18 million-$18.5 million.
- Management said client retention is the most immediate priority as churn remains higher than desired, with migration-related churn expected to persist generally through the end of 2027.
- The company ended the quarter with about $79 million in cash and no debt after the Vitalware divestiture and credit facility retirement.
- Bookings were better than expected, and management now expects to exceed the high end of its $22 million-$26 million bookings target for the year.
Third-quarter revenue was $56.3 million, above guidance of $55 million-$56 million. Adjusted EBITDA was $779,000, above guidance of break-even to $500,000, and adjusted net loss per share was negative $0.03. Revenue broke out to $40.7 million of technology revenue and $15.6 million of professional services revenue. Adjusted gross margin was 44.3% versus 52.6% in the prior-year period; adjusted technology gross margin was 60.6%; and adjusted professional services gross margin was 1.7%. For full-year 2026, management reaffirmed revenue guidance of $246 million-$249 million and adjusted EBITDA guidance of $18 million-$18.5 million. Fourth-quarter adjusted EBITDA is expected to be a loss of negative $1.8 million to negative $1.3 million, and full-year adjusted gross margin is expected to be below 50%, with adjusted technology gross margin in the low 60s and adjusted professional services gross margin in the low to mid-teens.
Simeon Kohl said Health Catalyst has strong healthcare expertise, longstanding client relationships, and meaningful assets, but he framed the immediate task as strengthening the company’s foundation. His four priorities were retention, greater cost alignment, less complexity, and more consistent execution. He was candid that churn is too high and said the company expects to be generally through migration-related churn headwinds by the end of 2027, while emphasizing discipline, transparency, and accountability.
Jason Alger highlighted that Q3 revenue and adjusted EBITDA exceeded guidance, but also noted margin pressure from the Vitalware divestiture, lower services revenue, and higher internal medical claims costs. He said internal benefits costs related to medical claims were about $1.6 million higher than expected across the business, with about half in cost of revenue and half in operating expenses. He also said the company ended the quarter with about $79 million in cash equivalents and short-term investments and no debt, and expects cash to decline modestly in Q4 due mainly to vendor payment timing, including a large prepayment for hosting infrastructure. He reiterated that Project Nexus savings are tracking to plan and that the company is managing with cash discipline.
There was no analyst Q&A session because no questions were queued. Management therefore did not have to address follow-ups on guidance, churn, margins, or the turnaround plan beyond the prepared remarks. The closest thing to Q&A was management’s own added color on churn pressure, bookings strength, and the decision to terminate an unprofitable interoperability relationship at year-end.
The quarter came in ahead of guidance on both revenue and adjusted EBITDA, and management said bookings remain strong enough to exceed the high end of the annual target. The balance sheet also looks cleaner after the Vitalware divestiture and debt retirement, with about $79 million in cash and no debt, giving the company flexibility to execute on its reset.
Management was explicit that churn remains elevated and that migration-related pressure will continue to weigh on reported results through 2027. Margins also fell sharply year over year, with adjusted gross margin down to 44.3% from 52.6%, and Q4 is expected to show a loss as Vitalware rolls off fully and medical claims costs stay elevated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.2%
- Shares Outstanding
- 76.16M
- Float Shares
- 59.56M
of shares held by institutions
137 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 12.75M | ▼ 62.09K |
| Cdc Financial, Inc. | 6.86M | ▼ 233.00K |
| Palogic Value Management, L.P. | 5.37M | ▲ 452.51K |
| Vanguard Group Inc | 4.43M | ▲ 138.70K |
| Impax Asset Management Group PLC | 4.00M | 0 |
| Vanguard Capital Management LLC | 2.75M | ▼ 219.78K |
| Blackrock, Inc. | 1.59M | ▼ 248.15K |
| Acadian Asset Management LLC | 1.05M | ▲ 908.23K |
| Marshall Wace, Llp | 1.05M | ▲ 1.05M |
| Mink Brook Asset Management LLC | 925.51K | ▲ 187.23K |
| Highmark Wealth Management LLC | 871.08K | 0 |
| Geode Capital Management, LLC | 793.95K | ▼ 97.41K |
Held by 59 ETFs
Biggest fund positions in HCAT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Landry Benjamin | sell | 70,000 |
| Nov 12, 26 | Landry Benjamin | sell | 29,478 |
| Oct 1, 26 | Reller Tami | other | 128,851 |
| Oct 1, 26 | Reller Tami | other | 0 |
| Sep 14, 26 | Kohl Simeon | buy | 59,000 |
| Sep 14, 26 | Kohl Simeon | other | 2,747,385 |
| Sep 14, 26 | Kohl Simeon | other | 0 |
| Sep 10, 26 | Albert Benjamin | other | 35,244 |
| Sep 1, 26 | Larson-Green Julie | other | 9,766 |
| Sep 1, 26 | Alger Jason | other | 17,973 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HCAT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on HCAT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Health Catalyst, Inc. (HCAT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Health Catalyst (HCAT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Health Catalyst (HCAT) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Here's What Key Metrics Tell Us About Health Catalyst (HCAT) Q3 Earnings
zacks.com · Nov 5
Health Catalyst Reports Third Quarter 2026 Results
globenewswire.com · Nov 5
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026
globenewswire.com · Oct 22
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 14
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
prnewswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
